Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × belzutifan × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 21 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 2 Neoplasm Metastasis 2 Recurrence 1 Pheochromocytoma 1 Paraganglioma 1 Neuroectodermal Tumors, Primitive 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1

Interventions

pembrolizumab 7 padeliporfin 4 Nivolumab 4 Everolimus 4 Sunitinib 3 Sorafenib 3 Mitomycin 3 fludarabine 2 durvalumab 2 cabozantinib 2 Cyclophosphamide 2 Cisplatin 2 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2 volociximab 1 vinflunine 1 sipuleucel-T 1 pemigatinib 1 palladium-bacteriopheophorbide 1 obinutuzumab 1 luprolide acetate gel depot 1 lenvatinib 1 ixabepilone 1 fludarabine phosphate 1 epothilone B 1 enzalutamide 1 belzutifan 1 atezolizumab 1 advexin 1 Vitamin B 12 1 Therapeutics 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07227402 2026-03-16

LITESPARK-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡